- Jonathan M. Rigby, Roger Hawley
- San Diego, CA
- Went Public on Nov 23, 2010
- Health Care, Biotechnology
- Zogenix engages in the development and commercialization of products for the treatment of central nervous system disorders and pain.
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.
We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.
Current Team (6)Update
Funding Rounds (6) - $167.1MUpdate
Board Members and Advisors (4)Update
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on...
Scale Venture Partners invests in early-in-revenue technology companies involved in SaaS-based,...
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600...
Chicago Growth Partners (CGP) is a Midwest US based private equity firm that provides expansion...
Clarus Ventures is a life sciences venture capital firm.
Life sciences & healthcare
Premier angel investment group
12671 High Bluff Dr
San Diego, CA 92130